Alzheimer’s Disease: A Clinical Practice-Oriented Review
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Investigation in the field of Alzheimer's disease (AD), the commonest cause of dementia, has been very active in recent years and it may be difficult for the clinician to keep up with all the innovations and to be aware of the implications they have in clinical practice. The authors, thus, reviewed recent literature on the theme in order to provide the clinician with an updated overview, intended to support decision-making on aspects of diagnosis and management. This article begins to focus on the concept of AD and on its pathogenesis. Afterward, epidemiology and non-genetic risk factors are approached. Genetics, including genetic risk factors and guidelines for genetic testing, are mentioned next. Recommendations for diagnosis of AD, including recently proposed criteria, are then reviewed. Data on the variants of AD is presented. First approach to the patient is dealt with next, followed by neuropsychological evaluation. Biomarkers, namely magnetic resonance imaging, single photon emission tomography, FDG PET, PiB PET, CSF tau, and Aβ analysis, as well as available data on their diagnostic accuracy, are also discussed. Factors predicting rate of disease progression are briefly mentioned. Finally, non-pharmacological and pharmacological treatments, including established and emerging drugs, are addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 5×
“In summary, AD genetic risk factors may be divided into: (1) rare autosomal dominant mutations (APP, PSEN1, PSEN2) – genetic tests available in selected circumstances; (2) common mutations with moderate effect (APOE) – genetic testing not recommended at present due to limited clinical utility and poor predictive value…”
BackgroundInfluentialCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187 · cited 2×
“The direct effect of glucose-mediated toxicity and hyperinsulinemia on amyloid metabolism and AD neurodegenerative processes has been emphasized (Biessels et al., 2006), but the exact pathophysiological mechanisms remain unclear.”
BackgroundAn active and socially integrated lifestyle in late life might protect against dementia
Fratiglioni, L., Paillard-Borg, S., & Winblad, B. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00767-7 · Cited by 2,135
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 2×
“…of the GWAS resulted in the identification of nine novel loci associated with late-onset AD: CLU, PICALM, CR1, BIN1, ABCA7, MS4A cluster (MS4A6A/MS4A4E), CD2AP, CD33, and EPHA1 (Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010; Hollingworth et al., 2011a,b; Naj et al., 2011).”
BackgroundInfluentialRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 1×
“The mutations in any of these three genes result in a shift in the metabolism of APP such that more of a 42 aminoacid form of Aβ is produced (Hardy, 1997).”
BackgroundStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · cited 1×
“In the early 1990s, the association between the APOE gene and late-onset AD was described (Corder et al., 1993; Saunders et al., 1993; Strittmatter et al., 1993a,b).”
BackgroundAlzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease
Rovio, S., Kåreholt, I., Helkala, E.-L., Viitanen, M., Winblad, B., Tuomilehto, J., Soininen, H., Nissinen, A., & Kivipelto, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70198-8 · Cited by 1,054
Cognitive Reserve and Alzheimer Disease
Stern, Y. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213815.20177.19 · Cited by 838 · cited 1×
“Thus, stimulating environments and physical exercise can be protective factors and may modulate the threshold of clinical expression of AD pathology (Fratiglioni et al., 2004; Stern, 2006).”
BackgroundNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806 · cited 1×
“AD rates rise from 2.8 per 1000 person-years in the age group 65–69 years to 56.1 per 1000 person-years in the older than 90-year age group (Kukull et al., 2002).”
BackgroundInfluentialCampion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758
Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study
Ruitenberg, A., den Heijer, T., Bakker, S. L. M., van Swieten, J. C., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20493 · Cited by 733
APOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · cited 1×
“Autosomal dominant disease is usually found in early onset AD families (Bertram and Tanzi, 2005).”
BackgroundEarly Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Andersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655
Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies
Andersen, K., Launer, L. J., Dewey, M. E., Letenneur, L., Ott, A., Copeland, J. R. M., Dartigues, J.-F., Kragh–Sorensen, P., Baldereschi, M., Brayne, C., et al. (1999) · Neurology · doi:10.1212/wnl.53.9.1992 · Cited by 650
Sex Differences in the Clinical Manifestations of Alzheimer Disease Pathology
Barnes, L. L., Wilson, R. S., Bienias, J. L., Schneider, J. A., Evans, D. A., & Bennett, D. A. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.685 · Cited by 643
Perry, G., Friedman, R., Shaw, G., & Chau, V (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3033 · Cited by 623 · cited 1×
“Tau protein is the main constituent of NFT, but other proteins have been identified, such as ubiquitin (Perry et al., 1987), cholinesterases (Mesulam and Moran, 1987) and A4 amyloid protein (Hyman et al., 1989).”
BackgroundPathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622 · cited 1×
“PATHOGENESIS AD is the most frequent cerebral proteopathy (Jucker and Walker, 2011).”
BackgroundVisser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608
Focal cortical presentations of Alzheimer's disease
Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., & Hodges, J. R. (2007) · Brain · doi:10.1093/brain/awm213 · Cited by 581 · cited 5×
“Half of the cortical basal syndrome (CBS) cases, about 40% of the patients with the non-fluent aphasia syndrome and a small percentage with behavioral FTLD and semantic dementia syndromes had AD pathology (Alladi et al., 2007).”
BackgroundInfluentialCoon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
Minoshima, S., Foster, N. L., Sima, A. A. F., Frey, K. A., Albin, R. L., & Kuhl, D. E. (2001) · Annals of Neurology · doi:10.1002/ana.1133 · Cited by 560
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Synaptic degeneration in Alzheimer's disease
Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517 · cited 5×
“The deleterious effects of these pathological changes provide the substrate for the etiopathogenesis of AD, and converge, ultimately, to synaptic dysfunction and neuronal cell loss (Götz et al., 2004; Walsh and Selkoe, 2004; LaFerla and Oddo, 2005; Arendt, 2009; Takahashi et al., 2010).”
BackgroundInfluentialAlzheimer and frontotemporal pathology in subsets of primary progressive aphasia
Mesulam, M., Wicklund, A., Johnson, N., Rogalski, E., Léger, G. C., Rademaker, A., Weintraub, S., & Bigio, E. H. (2008) · Annals of Neurology · doi:10.1002/ana.21388 · Cited by 513
Head injury and the risk of AD in the MIRAGE study
Guo, Z., Cupples, L. A., Kurz, A., Auerbach, S. H., Volicer, L., Chui, H., Green, R. C., Sadovnick, A. D., Duara, R., DeCarli, C., et al. (2000) · Neurology · doi:10.1212/wnl.54.6.1316 · Cited by 506
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia
Rabinovici, G. D., Jagust, W. J., Furst, A. J., Ogar, J. M., Racine, C. A., Mormino, E. C., O'Neil, J. P., Lal, R. A., Dronkers, N. F., Miller, B. L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21451 · Cited by 477
Incidence of dementia: does gender make a difference?
Ruitenberg, A., Ott, A., van Swieten, J. C., Hofman, A., & Breteler, M. M. B. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00231-7 · Cited by 467
Xie, J., Brayne, C., & Matthews, F. E. (2008) · BMJ · doi:10.1136/bmj.39433.616678.25 · Cited by 438
Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434
Heart Failure and Risk of Dementia and Alzheimer Disease: A Population-Based Cohort Study
Qiu, C., Winblad, B., Marengoni, A., Klarin, I., Fastbom, J., & Fratiglioni, L. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1003 · Cited by 411
THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMERʼS DISEASE
Terry, R. D. (1963) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196310000-00005 · Cited by 403 · cited 1×
“Microscopically, its neuropathological hallmarks are the combined presence of extracellular β–amyloid-containing plaques and intraneuronal NFTs, the latter being formed by abnormally hyperphosphorylated tau protein (Terry, 1963; Alzheimer et al., 1995).”
BackgroundGoldman, J. S., Hahn, S. E., Catania, J. W., Larusse-Eckert, S., Butson, M. B., Rumbaugh, M., Strecker, M. N., Roberts, J. S., Burke, W., Mayeux, R., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821d69b8 · Cited by 393
Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Synaptic slaughter in Alzheimer's disease
Coleman, P. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.001 · Cited by 351 · cited 2×
“Several studies using AD human samples have found reduced expression of a group of genes encoding proteins involved in synaptic vesicle traffic, with consequent depletion of neurotransmitter systems and synaptic/neuronal loss (Coleman and Yao, 2003; Yao et al., 2003).”
BackgroundWirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., & Bayer, T. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01876-6 · Cited by 336
Is the Risk of Developing Alzheimer's Disease Greater for Women than for Men?
Hebert, L. E., Scherr, P. A., McCann, J. J., Beckett, L. A., & Evans, D. A. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.2.132 · Cited by 331
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
Schoonenboom, N. S. M., Reesink, F. E., Verwey, N. A., Kester, M. I., Teunissen, C. E., van de Ven, P. M., Pijnenburg, Y. A. L., Blankenstein, M. A., Rozemuller, A. J., Scheltens, P., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31823ed0f0 · Cited by 302
Pan, X.-D., Zhu, Y.-G., Lin, N., Zhang, J., Ye, Q.-Y., Huang, H.-P., & Chen, X.-C. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-45 · Cited by 292
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279 · cited 1×
“The β-amyloid (Aβ) peptide and tau protein are thought to play a critical role in AD development, but several other mechanisms of neurodegeneration have been proposed, including pro-inflammatory responses (Wyss-Coray, 2007), mitochondrial dysfunction (Reddy, 2011), oxidative stress (Cai et al., 2011),genetic and envir…”
BackgroundPorsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease
Wingo, T. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.221 · Cited by 265
Tschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., Mielke, M. M., Piercy, K., Steinberg, M., Rabins, P. V., et al. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181faec23 · Cited by 244
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237
Kalmijn, S., Launer, L. J., Lindemans, J., Bots, M. L., Hofman, A., & Breteler, M. M. B. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010000 · Cited by 237
Adiposity indices and dementia
Gustafson, D. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70526-9 · Cited by 237 · cited 1×
“, 2005), possibly through vascular dysfunction or through the effects of hormonal compounds that are secreted by the adipose tissue (Gustafson, 2006).”
BackgroundLong-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230
Tam, C. W. C., Burton, E. J., McKeith, I. G., Burn, D. J., & O’Brien, J. T. (2005) · Neurology · doi:10.1212/01.wnl.0000153070.82309.d4 · Cited by 209
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208
The significance of medial temporal lobe atrophy: A postmortem MRI study in the very old
Barkhof, F., Polvikoski, T. M., van Straaten, E. C. W., Kalaria, R. N., Sulkava, R., Aronen, H. J., Niinistö, L., Rastas, S., Oinas, M., Scheltens, P., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000277459.83543.99 · Cited by 204
Regional synaptic pathology in Alzheimer's disease
Honer, W. G., Dickson, D. W., Gleeson, J., & Davies, P. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90111-a · Cited by 179
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152 · cited 1×
“Welge et al. (2009) found that combining CSF p-tau with Aβ42/Aβ38 resulted in a sensitivity of 94% for detection of AD and 85% specificity for excluding non-AD dementias.”
BackgroundCo-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses
Takahashi, R. H., Capetillo-Zarate, E., Lin, M. T., Milner, T. A., & Gouras, G. K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.021 · Cited by 150
Cardiovascular disease and cognitive performance in middle-aged and elderly men
Muller, M., Grobbee, D. E., Aleman, A., Bots, M., & van der Schouw, Y. T. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.01.005 · Cited by 147 · cited 1×
“…the view that chronic cerebral hypoperfusion may promote selective neurodegenerative damages in susceptible brain areas (Ruitenberg et al., 2005) and suggesting that peripheral atherosclerosis biomarkers can be early indicators of a subclinical phase of AD (Qiu et al., 2006; Muller et al., 2007).”
BackgroundGenetics of Alzheimer's disease: recent advances
Avramopoulos, D. (2009) · Genome Medicine · doi:10.1186/gm34 · Cited by 136
Lethality of Alzheimer Disease and Its Impact on Nursing Home Placement
Arrighi, H. M., Neumann, P. J., Lieberburg, I. M., & Townsend, R. J. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31819fe7d1 · Cited by 126 · cited 1×
“Nursing home admission by the age of 80 years is expected for ∼75% of the surviving AD patients, and only for 4% of the general population (Arrighi et al., 2010).”
BackgroundAn inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease
Roses, A. D. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.88 · Cited by 118 · cited 1×
“Recently, a variable-length poly-T (deoxythymidine homopolymer) polymorphism in the TOMM40 gene, which is located next to the APOE gene in a region of strong linkage disequilibrium, was described and found to be associated with the age of onset of late-onset AD (Lutz et al., 2010; Roses, 2010; Roses et al., 2010).”
BackgroundAntemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND
Vemuri, P., Simon, G., Kantarci, K., Whitwell, J. L., Senjem, M. L., Przybelski, S. A., Gunter, J. L., Josephs, K. A., Knopman, D. S., Boeve, B. F., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.12.073 · Cited by 108
Seshadri, S., Beiser, A., Au, R., Wolf, P. A., Evans, D. A., Wilson, R. S., Petersen, R. C., Knopman, D. S., Rocca, W. A., Kawas, C. H., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.002 · Cited by 97
Gender differences in predictors of mortality in nursing home residents with AD
Lapane, K. L., Gambassi, G., Landi, F., Sgadari, A., Mor, V., & Bernabei, R. (2001) · Neurology · doi:10.1212/wnl.56.5.650 · Cited by 91
Ultrastructural Localization of Intraneuronal Aβ-Peptide in Alzheimer Disease Brains
Gómez-Ramos, P., & Asunción Morán, M. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11109 · Cited by 76
Inflammatory Proteins in Plasma and the Risk of Dementia: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.668 · Cited by 10
Cited by
Shi, J., Zheng, X., Li, Y., Zhang, Q., & Ying, S. (2018) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2017.2655720 · Cited by 444
“The identifiable imaging biomarkers have been effectively utilized for the diagnosis or prognosis of AD, due to their advantages of visualization and quantitative measurement of brain structural and functional information by neuroimaging [5]–[7].”
The impact of obesity on neurodegenerative diseases.
Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.002 · Cited by 185
Downregulated serum miR‐223 servers as biomarker in Alzheimer's disease
Jia, L., & Liu, Y. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3184 · Cited by 95
Metadata
- Authors
- Alves, L., Correia, A. S. A., Miguel, R., Alegria, P., & Bugalho, P.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 3
- Pages
- 63-63
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2031723788
- Cited by
- 68
- References
- 92
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.